[Effectiveness of echinacin in therapy of chronic recurrent respiratory disease].
OBJECTIVE
Echinacea purpurea (echinacin) is frequently used in the therapy of chronic recurrent respiratory disease. The aim of this study was to show whether treatment of chronic recurrent respiratory disease with echinacin has a greater benefit in terms of effectiveness than therapy without an immunomodulator.


METHODS
Frequency, duration of recurrence, resources used and patients' satisfaction was documented in order to assess benefit. In this prospective, non-randomised, multi-centre, nationwide, two-armed health services research study, data of 995 patients (782 echinacin-, 213 standard-cohort) with chronic recurrent respiratory disease were collected. The perspectives of statutory health insurance (SHI), patients and health policy were taken into consideration.


RESULTS
The risk of falling ill was 2.3 fold higher and the duration of relapse 1.4 days more compared to the standard-cohort. There was a clinical and economical benefit from the therapy with echinacin for SHI and health policies. In contrast, patients experienced a greater financial burden. Average total costs per patient during the observation period of 3 months amounted to 238.35 in the standard-cohort and to 228.95 in the echinacin-cohort. Results of the intent-to-treat-analysis were reconfirmed in a per-protocol-analysis.


CONCLUSIONS
This health services-research-study taking the therapy of chronic recurrent respiratory disease with echinacin as an example has shown that even non-prescription drugs can have clinical and economic benefits.
Heinen-Kammerer
T
T
Institut für Empirische Gesundheitsökonomie, Burscheid. info@ifeg.de
Holtmannspötter
C
C
Schnabel
S
S
Motzkat
K
K
Kiencke
P
P
Rychlik
R
R
D000328:Adult; D002908:Chronic Disease; D015331:Cohort Studies; D017046:Cost Savings; D003627:Data Interpretation, Statistical; D020900:Echinacea; D006302:Health Services Research; D006801:Humans; D017060:Patient Satisfaction; D010936:Plant Extracts / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012307:Risk Factors
D010936:Plant Extracts; C030210:echinacin